Porcine reproductive and respiratory syndrome (PRRS) is the most economically significant disease affecting the U.S. swine industry.1 Economic losses from PRRS have been estimated at $664 million annually in the United States, or $1.8 million per day.2 That represents a profit loss of $4.32 per pig, including losses due to poor performance and medication costs.2 Pigs infected with this viral disease have significantly worse average daily gain (ADG) and higher mortalities compared to pigs remaining PRRSV negative through to market.2
Maintaining uniform, vaccine-derived immunity helps mitigate the consequences of PRRSV infection, thus reducing the clinical impact of disease and improving pig health and performance.
Minimizing exposure and transmission is accomplished, in part, through adherence to biosecurity protocols, which helps reduce the level of PRRSV challenge within and from vaccinated populations.
Conducting regular diagnostic testing, auditing biosecurity protocols, and monitoring for changes in the herd provide the insight required to develop and implement the right solutions.
